Literature DB >> 11954816

Late complications of pelvic irradiation in 16 dogs.

Christine R Anderson1, Elizabeth A McNiel, Edward L Gillette, Barbara E Powers, Susan M LaRue.   

Abstract

When external beam radiation therapy is administered to the pelvis, normal tissues irradiated may include the colon, small intestine, urethra, bladder, bone, and spinal cord. The objectives of this retrospective study were to determine the incidence and severity of late radiation effects following pelvic irradiation in dogs and to identify factors that increase the risk of these effects. Medical records of all dogs treated with curative intent external beam radiation therapy to the pelvic region between 1993 and 1999 were reviewed. Patients with follow-up longer than 9 months or any patient that developed late complications earlier than 9 months were evaluated. Sixteen dogs met criteria for inclusion in this study. All dogs were treated with a 6-MV linear accelerator with bilaterally opposed beams. Diseases treated included transitional cell carcinoma of the bladder, transitional cell carcinoma of the prostate, and anal sac apocrine gland adenocarcinoma. Four dose/fractionation schemes were used: 49.5 Gy in 3.3 Gy fractions, 54 Gy in 3.0 Gy fractions, 54 Gy in 2.7 Gy fractions, and 18 Gy intraoperative radiation therapy followed by 43 Gy external beam radiation therapy in 2.9 Gy fractions. Implantable chemotherapy in the form of an OPLA-Pt sponge was used in six dogs as a radiation potentiator. Colitis was the major late effect following pelvic irradiation, occurring in nine dogs (56%). Colitis was characterized as mild in three dogs, moderate in one dog, and severe in five dogs. Three of the dogs with severe effects suffered gastrointestinal perforation. All dogs with severe late effects received 3 or 3.3 Gy per fraction, and 80% received radiation potentiators. In the seven dogs that received 2.7 Gy or 2.9 Gy per fraction, late effects were classified as none (n = 5), mild colitis (n = 1), and moderate colitis (n = 1). Radiation therapy can be administered to the pelvic region with a minimal risk of late effects to the colon by giving smaller doses per fraction and avoiding systemic radiation potentiators.

Entities:  

Mesh:

Year:  2002        PMID: 11954816     DOI: 10.1111/j.1740-8261.2002.tb01668.x

Source DB:  PubMed          Journal:  Vet Radiol Ultrasound        ISSN: 1058-8183            Impact factor:   1.363


  8 in total

1.  Clinical outcomes of dogs with transitional cell carcinoma receiving medical therapy, with and without partial cystectomy.

Authors:  Marcus L Bradbury; Christine M Mullin; Shaban D Gillian; Chick Weisse; Philip J Bergman; Michelle A Morges; Lauren R May; David M Vail; Craig A Clifford
Journal:  Can Vet J       Date:  2021-02       Impact factor: 1.008

2.  Chemotherapy and radiation therapy in 4 dogs with muscle-invasive transitional cell carcinoma of the urinary tract.

Authors:  Laura Marconato; Dagmar B Nitzl; Katja J Melzer-Ruess; Marcel A Keller; Julia Buchholz
Journal:  Can Vet J       Date:  2012-08       Impact factor: 1.008

3.  Pubectomy and stereotactic radiotherapy for the treatment of a non-resectable sacral osteosarcoma causing pelvic canal obstruction in a dog.

Authors:  Victoria D Randall; Sarah E Boston; Heather L Gardner; Lynn Griffin; Michelle L Oblak; Lyndsay Kubicek
Journal:  Can Vet J       Date:  2016-09       Impact factor: 1.008

4.  Laparoscopically implanted tissue expander radiotherapy in canine transitional cell carcinoma.

Authors:  Sean Murphy; Alonso Gutiérrez; Jessica Lawrence; Dale Bjorling; Thomas Mackie; Lisa Forrest
Journal:  Vet Radiol Ultrasound       Date:  2008 Jul-Aug       Impact factor: 1.363

5.  Radiation-induced sarcoma in a cat following hypofractionated, palliative intent radiation therapy for large-cell lymphoma.

Authors:  Matthew R Cook; Michael P Martinez; Joelle M Fenger; Noopur C Desai
Journal:  JFMS Open Rep       Date:  2019-11-27

Review 6.  Naturally-Occurring Invasive Urothelial Carcinoma in Dogs, a Unique Model to Drive Advances in Managing Muscle Invasive Bladder Cancer in Humans.

Authors:  Deborah W Knapp; Deepika Dhawan; José A Ramos-Vara; Timothy L Ratliff; Gregory M Cresswell; Sagar Utturkar; Breann C Sommer; Christopher M Fulkerson; Noah M Hahn
Journal:  Front Oncol       Date:  2020-01-21       Impact factor: 6.244

Review 7.  Comparative Cancer Cell Signaling in Muscle-Invasive Urothelial Carcinoma of the Bladder in Dogs and Humans.

Authors:  Maria Malvina Tsamouri; Thomas M Steele; Maria Mudryj; Michael S Kent; Paramita M Ghosh
Journal:  Biomedicines       Date:  2021-10-14

8.  Complete Resolution of a Recurrent Canine Anal Sac Squamous Cell Carcinoma with Palliative Radiotherapy and Carboplatin Chemotherapy.

Authors:  Antonio Giuliano; Jane Dobson; Sarah Mason
Journal:  Vet Sci       Date:  2017-09-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.